Leaders gather at the Milken Institute 2024 Future of Health Summit to address global health issues
Business Leaders and Industry Experts Join Top Policymakers to Address Pivotal Issues in Health Globally at the Milken Institute 2024 Future of Health Summit The Milken Institute 2024 Future of Health…
Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials
Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application…
Reverb Therapeutics to Collaborate With Royalmount Laboratories on Development of Advanced Bispecific Antibodies
Reverb Therapeutics, a leader harnessing the body’s immune system and cytokine signaling to treat life-threatening diseases, announced it has launched a collaboration with Royalmount Laboratories, based in Montreal, as Reverb…
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s…
VIVOLTA teams up with Neurochase to produce electrospun micro-catheters for advanced CNS brain therapies.
VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies to…
Kanvas Bio Presents Clinical Data on Gut Microbiome’s Role in Anti-Tumoral Immunity at SITC
Kanvas Biosciences, a spatial biology company, has unveiled clinical trial results at the 2024 Society for Immunotherapy of Cancer (SITC) meeting, showing the potential of fecal microbiota transplantation (FMT) in…
Brenus Pharma Publishes Positive Proof of Concept Results in Scientific Frontiers in Oncology
Brenus Pharma has announced the publication of a scientific article in Frontiers in Oncology detailing the results of its novel “off-the-shelf” cancer treatment. The company’s innovative platform replicates patients’ relapsing…
Baxter Announces Third-Quarter 2024 Financial Results
Baxter International Inc. (NYSE: BAX), a global leader in medical technology, today announced its financial results for the third quarter of 2024. “Baxter achieved strong performance in Q3 2024 as…
Free Heart and Kidney Health Screenings Offered in Houston from Nov. 11-14
Care Access, a global clinical research company focused on advancing medicine, is hosting a Heart & Kidney Health Screening event in Houston, Texas. The initiative is designed to raise awareness…
Tempus to Present Nine Abstracts at the 2024 Society for Immunotherapy of Cancer Annual Meeting
Tempus AI, Inc. (NASDAQ: TEM), a leader in utilizing AI to advance precision medicine and patient care, announced today that nine abstracts have been accepted for presentation at the Society…
BeiGene Showcases Innovative Hematology Portfolio for B-cell Malignancies at ASH 2024
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will present new data on a range of B-cell malignancies and treatments at the…
Tezspire Achieves Both Primary Goals in Phase III WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps
AstraZeneca and Amgen announced promising top-line results from the Phase III WAYPOINT trial, showing that Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with…